Φορτώνει......
Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
Venetoclax (ABT-199), a BH3-mimetic and selective BCL-2 inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) in adult patients aged 75 years or older, or otherwise unable to tolerate intensive induction chemotherapy, in combi...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Manag Res |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6499443/ https://ncbi.nlm.nih.gov/pubmed/31118772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S180724 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|